BioNTech Faces a Defining May: Shareholder Reshuffle, Founders' Farewell, and a High-Stakes Cancer Data Drop

BioNTech enters a period of rare simultaneity this month, with a shareholder vote on board restructuring scheduled for the same week that the oncology world will scrutinize its most advanced pipeline candidate. The convergence of corporate governance and clinical proof points comes as the company's founding scientists prepare to walk off the bridge, leaving investors to weigh the immediate noise against the longer-term direction.

Boardroom Overhaul Meets $6.9 Billion Retained Earnings

The virtual shareholder meeting, set for May 15, 2026, carries more weight than the typical annual ritual. BioNTech is proposing to expand its supervisory board from six to eight members, a move that mirrors its strategic reorientation toward oncology. Three incumbents are standing for re-election, while two new specialists in oncology and clinical development are slated to join.

Among the agenda items is the recommendation to carry forward the entire retained profit of around €6.9 billion, bypassing any dividend payout. Shareholders will also vote on a new authorized capital of up to €129.5 million—roughly half the current share capital—plus the appointment of EY as auditor, a profit transfer agreement with subsidiary BioNTech Discovery, and the approval of the compensation report.

The board expansion fits a narrative that the company is consciously redesigning its governance to oversee a multibillion-dollar transition. But a much more dramatic leadership story is unfolding in parallel.

Should investors sell immediately? Or is it worth buying BioNTech?

The Founders’ Exit and the Succession Search

Ugur Sahin and Özlem Türeci, the couple who built BioNTech from a Mainz lab into a global vaccine force, will step down as CEO and chief medical officer at the end of this year. They plan to launch a new biotechnology venture focused on next-generation mRNA innovations. A binding agreement for the spin-out is expected by mid-2025, under which BioNTech will license certain technology rights in exchange for a minority stake. The parent company has ruled out any ongoing financial support.

The supervisory board is now hunting for replacements. Analyst reaction has been measured but cautious. Leerink Partners called the departure a logical step for a maturing company but warned that the perceived leadership vacuum could weigh on sentiment in the near term. The stock took a sharp hit on the day of the announcement, marking its low for the year, and has only partially recovered since.

Pumitamig Takes Center Stage at ASCO

Just days after the shareholder meeting, BioNTech will present data from the phase 2 portion of the ROSETTA Lung-02 trial at the American Society of Clinical Oncology (ASCO) annual meeting. The drug in question is Pumitamig, a bispecific antibody being tested in combination with chemotherapy for non-small cell lung cancer. The study is comparing that regimen against pembrolizumab plus chemotherapy in a head-to-head design.

The phase 3 part of the trial is already enrolling patients, underscoring that this is no exploratory science project but a late-stage program with registration ambitions. BioNTech has also kicked off five new registration trials for Pumitamig, targeting breast, colorectal, gastric, and additional lung cancer settings.

Meanwhile, a second candidate, Gotistobart, has shown encouraging early data: a 54% reduction in the risk of death versus standard chemotherapy in lung cancer patients, with more interim readouts expected later in the year.

Financial Realities: Red Ink and a $1 Billion Buyback

The financials reflect the heavy lift of this transition. In the first quarter, revenue fell to $138 million (€118.1 million) as the Covid vaccine business continued to shrink. R&D spending surged to $651.6 million, contributing to a net loss of $622.3 million (€532 million). Despite the losses, management held its full-year guidance at $2.3–$2.6 billion in revenue.

BioNTech at a turning point? This analysis reveals what investors need to know now.

BioNTech's cash position remains formidable, standing at $19.6 billion (roughly €18 billion). The company has also authorized a stock repurchase program of up to $1 billion over the next twelve months, an attempt to signal confidence amid the turbulence.

The Market’s Muted Reaction

Investors, however, have not been buying the optimism. The stock traded at around €79.60 on the Frankfurt exchange, down about 5.5% from a month ago and nearly 8.6% below its 200-day moving average. A separate report quoted a level of €79.70, reflecting a narrow trading range. The shares remain well below their long-term average and have only modestly recovered from the trough set on the day of the founders' resignation announcement.

May thus delivers two concrete milestones. The shareholder meeting will show whether institutional investors back the governance overhaul and the executive succession plan. The ASCO data on Pumitamig will provide the first hard evidence on whether BioNTech's ambitious oncology pipeline has the clinical heft to support the next growth phase. Both events will shape the narrative as the company prepares for the quieter—but equally consequential—task of finding a new captain for the bridge.

Ad

BioNTech Stock: New Analysis - 13 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69323066 |